Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth high flyer confirmed it would soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback